[ad_1]
The Dow Jones futures changed little on Tuesday night, as did the S & P 500 and Nasdaq futures, following the current rally in the stock market, which reached a new milestone during the regular session. . At the end of the session, the Dow Jones drug giant Merck (MRK) reported the results of the Keytruda liver cancer trial, while software stocks Five (FIVN) Cadence design systems (CDNS) and OneSpan (OSPN) published the results. The Merck share fell slightly at the end of the session, close to a point of purchase. Five9 shares, Cadence Design and OneSpan all made strong progress.
X
Dow Jones Futures Today
Dow Jones futures increased 0.1% over fair value. Futures on the S & P 500 were slightly higher. Nasdaq 100 futures were up 0.2%. Do not forget that day-to-day futures trading on Dow and elsewhere do not necessarily translate into actual trading at the next regular trading session.
Current stock market rally
The major averages collapsed, but the Dow Jones posted a gain on Tuesday's stock market. The S & P 500 index rose 0.15% and the Nasdaq composite 0.2%. The Nasdaq has moved a little further than its 200-day line. On December 3, the techno-heavy index surpassed its peak intra-day peak just before the stock market correction hits the overdrive. The current stock market rally enabled the Dow Jones and Nasdaq to make gains for eight consecutive weeks. Once the major averages have erased their December highs, the market rally can move towards the unprecedented highs of late September or early October. Only then will we have an idea that the current stock market rally marks the beginning of a new long-term bull market. But for now, this is a market recovery negotiable.
Market Research on Liver Cancer at Merck Stock
Merck's Keytruda immunotherapy drug failed a phase 3 trial involving a specific type of liver cancer. The pharmaceutical giant Dow Jones is testing Keytruda, already approved for certain cancers, for several others.
The Merck stock fell 1.1% late. This is not a big move, especially after trading hours. But Merck shares are trading just below a fixed base purchase point of 80.29. Shares climbed to 80.13 on Tuesday internally before reversing to close down 0.7% to 79.24.
Five9 profit sends Five9 stock to a new record
In the fourth quarter, Five9's earnings jumped 228% to 23 cents a share, while revenue increased 31% to $ 72.3 million. Analysts expect a profit of Five9 of 14 cents per share on a turnover of 66.5 million dollars. The cloud-based consumer contact software manufacturer has guided EPS EPS in the first quarter online and slightly higher revenues.
Five stocks9 rose 6.8% late, a sign of a new high. IBD 50 member shares are extended from a purchase point of 49.60 from a late base. Five stocks9 rose 0.1% to 54.31 on Tuesday.
The relative strength is at a record level. The Five9 stock has a better IBD composite rating of 99.
Cadence design gains
Cadence Design earnings increased 33 percent to 52 cents per share in the fourth quarter, while sales increased 14 percent to $ 570 million. Analysts expect a 48-cent profit for Cadence on a $ 551-million business, according to Zacks Investment Research. Cadence Design guided higher for Q1.
The title Cadence Design appeared late by 8.9%, which indicates a record. Shares of the chip design software maker rose 0.1 percent to 52.64 on Tuesday. The stock of Cadence Design is expanded from 47.50 points of purchase. Cadence Design has a composite rating of 97 IBD.
Surprise of OneSpan Results, Stocks in OneSpan
The profits of OneSpan unexpectedly increased by 21% to 17 cents per share. Analysts expected a profit of OneSpan down 7 cents. Revenue rose 19% to $ 64.8 million, the largest increase in cybersecurity stock in more than four years. OneSpan expects current year revenues to increase from $ 229 million to $ 237 million. The midpoint of $ 233 million is above consensus for $ 230 million.
The OneSpan stock climbed 27% to 21.25 at the end of the session. This marks a big move above the 200-day mark for an eight-month high. OneSpan shares recently broke a downtrend. Its potential buying point is 25.55, just above the peak of June 2018. The OneSpan stock rose 3.8 percent to 16.77 on Tuesday.
The benefits of OneSpan being uneven and the share price lagging, the title is weakly noted.
You might also like:
Overview: 3 reasons why this rally can continue to run
Copper prices signal the Dow Jones Bulls: the year 2016 is back again
After trading hours: here is what it is and why it can help you on the stock market
How many growth stocks to own? Here is the best way for a great return
[ad_2]
Source link